Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Indomethacin and Pantoprazole

PreclinicalSmall molecule

LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Indomethacin and Pantoprazole is one of 2 small molecule programs targeting Heterotopic Ossification. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heterotopic OssificationUnknown status

Heterotopic OssificationPreclinical

Unknown status

Competition

Competitive Landscape

2 competitors in Heterotopic Ossification

#DrugCompanyPhaseTrials

Aredia

HHikma Pharmaceuticals LLC

Indomethacin and Pantoprazole

LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Heterotopic Ossification1 trial

Indomethacin Prophylaxis for Heterotopic Ossification After Surgical Treatment of Elbow Trauma

Unknown status·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·N/A·NCT01744314·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Indomethacin and Pantoprazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Indomethacin and Pantoprazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Indomethacin and Pantoprazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Related News